VANCOUVER, BC and COFFS HARBOUR, Australia, Nov. 20, 2025 /PRNewswire/ — WhiteWater is thrilled to announce a new strategic partnership with Swimplex Aquatics to bring the world’s leading water park products and services to Australia. Combining WhiteWater’s global expertise with Swimplex’s deep local knowledge, the collaboration will strengthen support for developers, accelerate project delivery, and elevate aquatic experiences across the Australian market.

WhiteWater, the global leader in water park and aquatic attraction design and manufacturing, has been creating iconic and world-class attractions since 1980. Swimplex Aquatics, established in 1985, is Australia’s leading specialist in the design, supply and construction of commercial aquatic facilities. Together, the two companies will provide the most comprehensive portfolio in the industry and end-to-end solutions for councils, developers, and private operators across the country, creating safe and fun places where families unite to make joyful lasting memories.

“At WhiteWater, our product strength has always been innovation grounded in engineering excellence to prioritize safety, guest experience, and sustainability. We have delivered over 6,000 projects globally, creating immersive experience and delighting guests all over the world,” said David Bogdonov, Community Aquatics Director at WhiteWater, “By combining our award-winning slides and aquatic play, plus the best stationary wave with FlowRider, with Swimplex’s best in class service, this partnership provides the highest quality aquatic entertainment solutions on the market in Australia. We’re excited to support local developers in creating destinations that rival the best water parks around the world.”

As a trusted leader in the commercial pool and waterslide industry, Swimplex Aquatics has successfully completed projects across every Australian state and New Zealand. Its integrated service model covers every stage of project delivery—from concept design and detailed engineering to installation, commissioning, and ongoing maintenance—ensuring efficiency, quality, and a seamless client experience.

“Partnering with WhiteWater marks an exciting new chapter for Swimplex Aquatics,” said Daniel Leaver, Swimplex Aquatics Director, “Together, we’re uniting global innovation with local expertise, bringing world-class slides, surf and wave systems, aquatic play, and water ride experiences to Australia. It’s a collaboration built on trust, expertise, and a shared commitment to quality. Every community deserves exceptional aquatic experiences, and by joining forces with WhiteWater, we’re setting new standards for what’s possible in the Australian market.”

The partnership’s first project—soon to be announced—will showcase a complex of WhiteWater slides and splash pads, serving as a benchmark for the kind of family-oriented entertainment that the two companies aim to deliver nationwide.

The partnership marks a new chapter for Australia’s aquatic leisure industry.   As families increasingly seek meaningful, shared experiences and developers look to create destinations that entertain guests of all ages, the collaboration between WhiteWater and Swimplex Aquatics arrives at the perfect time. Together, they will elevate the standard of aquatic entertainment across the country and look forward to shaping a future where Australian aquatic attractions set new global benchmarks for creativity, quality, and sustainability.

About WhiteWater

WhiteWater was born in 1980 with one clear purpose, to create places where families unite and make joyful lasting memories.

We achieve this by standing alongside our customers from concept to completion of award-winning attractions, from slides to water rides and everything in between. We aim to inspire our clients by unleashing our creativity to realize their ambitions; we craft solutions which make each park unique. We are dedicated to making products that operators can count on, because we understand the importance of reliability and efficiency on the bottom line. 

As market leaders, we put our success down to our attitude, in all our years we’ve never once forgotten why we’re here – to help parks solve problems, create immersive experiences, and delight guests all over the world.

We’re here to create places where fun can thrive.

Website: https://www.whitewaterwest.com/en/australias-water-park-leader/

About Swimplex Aquatics

Swimplex Aquatics are a world-class company dedicated to the commercial pool, water slide industry. We are Australian market leaders servicing all states Australia wide. Swimplex provide a full comprehensive water slide package from design, engineering through to civil works, installation and after sales service. We can deliver an innovative water slide project for any budget.

Our specialist services include pool construction, renovation, refurbishment, filtration, heating, waterslides and the manufacture of innovative pool products. We also specialize in the installation of Myrtha Pools and water treatment plants in addition to the manufacture and supply of our own quality proprietary products including WETDECK© grating, lane ropes, starting platforms and pool covers.

Our extensive experience and expertise combined with quality and value means you can be assured of a first-class outcome.

VANCOUVER, BC, Nov. 20, 2025 /PRNewswire/ — Wondershare, a global leader in creativity and productivity solutions, launches EdrawMind V13, an AI-powered mind mapping software with built-in notes. As one of the first professional tools to support node-based notes, the new release delivers a faster, smarter, and more precise knowledge management system — redefining the productivity boundaries of mind mapping.

The latest version introduces a series of powerful updates — from smarter knowledge management and next-generation creative tools to enhanced AI capabilities — all designed to make idea organization more intuitive and inspiring than ever.

Smarter Knowledge Management

EdrawMind V13 introduces a new note system that allows users to insert and edit notes directly in a dual-pane view. The mind map on the left offers a clear structural overview, while the notes on the right capture detailed context. The mind map with notes becomes a visualized knowledge base, which can be tracked and consulted at any time. Users can insert text, images, videos, tables, links, code blocks, thus meeting diverse content-management needs.

Next-Generation Mind Map

From “node connection” to “free creation”, EdrawMind V13 ushers in a new era of creative flexibility. The new version supports flowcharts (shape and plain text), free drawing of relationship lines (auto-routing), and note sketching, thereby seamlessly merging the whiteboard-like creative freedom with the structured clarity of a mind map.

Advanced AI Capability

The new version introduces the AI Webpage Summarizer, which supports one-click intelligent summarization of website content, automatically transforming complex information into structured knowledge networks within seconds.

The AI Summarizer intelligently generates notes for key nodes, turning mind maps into structured knowledge bases.

The new version also supports an AI web search feature, enabling users to generate up-to-date mind maps and presentations — complete with citation sources for one-click traceability.

Enhanced User Experience

The redesigned workspace features a cleaner, more intuitive interface with a left-panel entry for AI-Generated Mind Maps, simplifying the access to AI features. Eight new thematic styles cater to different creative scenarios and visual preferences, making knowledge mapping both powerful and effortless.

“With EdrawMind V13, we’re reimagining how individuals and teams think, create, and organize knowledge,” said Aiden, Head of Wondershare EdrawMind. “By combining AI intelligence with intuitive design, we’re empowering users to transform information into insight faster and more intelligently than ever before.”

Visit EdrawMind’s official website or follow EdrawMind on YouTube, Facebook, Twitter, Linkedin, and Instagram to get more information about EdrawMind.

About Wondershare:

Wondershare is a globally recognized software company founded in 2003, known for its innovative solutions in creativity and productivity. Driven by the mission “Creativity Simplified”, Wondershare offers a range of tools, including Filmora, SelfyzAI for video editing; PDFelement for document management; and EdrawMax, EdrawMind for diagramming. With over 2 billion cumulative active users across all products and a presence in over 200 countries and regions, Wondershare empowers the next generation of creators with intuitive software and trendy creative resources, continually expanding the possibilities of creativity worldwide.

MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®^[1], ⁸⁹Zr-DFO-girentuximab) PET/CT^[2] would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26^th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ, December 2 – 5, 2025.

ZIRCON-X was a non-interventional, prospective, post-hoc study sponsored by Telix – using imaging data from Telix’s parent pivotal Phase 3 ZIRCON study^[3] – that assessed the impact of TLX250-CDx imaging on clinical decision-making versus SOC contrast-enhanced diagnostic imaging in 294 patients with indeterminate renal masses (IRMs)^[4]. The study found that 143 patients (48.6%) would have undergone a change in clinical management if imaged with TLX250-CDx, and over 20% of these patients (31 out of 143) could have potentially avoided invasive biopsy^[5].

Of all evaluable patients, more than one third (110 out of 294, or 37.4%) would have had a major change in clinical management based on defined categories (see table below), with approximately 30% having their treatment escalated or de-escalated.  A subset of 18 patients initially selected for active surveillance would have been escalated to immediate treatment^[5]. 

In patients whose planned surgery was changed, TLX250-CDx provided greater clarity on spatial localization of ccRCC within the kidney; thus allowing the physician to determine the most appropriate surgical procedure. 

Professor Karolien Goffin, staff member of nuclear medicine at the University Hospital Leuven,  Chair of the EANM Oncology & Theranostics Committee and a Principal Investigator on the ZIRCON and ZIRCON-X studies commented, “These are compelling results which demonstrate that TLX250-CDx PET/CT has significant potential to impact clinical decision making in the diagnostic work-up of patients presenting with small IRMs and give physicians greater confidence in clinical planning.”

Dr. David N. Cade, Group Chief Medical Officer at Telix, added, “This analysis is another demonstration of the potential clinical usefulness of TLX250-CDx, Telix’s breakthrough^[6] precision diagnostic candidate, which has recently been added to international guidelines for renal imaging^[7]. These results indicate that TLX250-CDx may deliver on an unmet need for better non-invasive diagnostic work-up for ccRCC that can improve risk stratification and minimize overtreatment and undertreatment.” 

About ZIRCON-X

ZIRCON-X was a non-interventional, prospective, post-hoc study assessing imaging data collected during Telix’s parent pivotal Phase 3 ZIRCON study. The primary objective was to assess whether TLX250-CDx PET/CT has an impact on clinical decision-making versus SOC conventional contrast-enhanced diagnostic imaging in patients presenting with an IRM.

Four multi-disciplinary teams^[8] (MDTs) at four separate institutions^[9] evaluated ZIRCON data from 294 evaluable patients in two steps:

Step 1: MDTs issued a patient management decision based on SOC conventional imaging and clinical/laboratory data (excluding histology)

Step 2: After a minimum 4-week interval, MDTs reassessed the same cases, this time informed by the TLX250-CDx PET/CT imaging results and the same clinical/laboratory data^[10]

Clinical management for each individual patient was determined by MDT consensus. Data will support Telix’s planned marketing authorization application for TLX250-CDx in Europe.

About TLX250-CDx

TLX250-CDx is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on >95% of ccRCC cells^[11], to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency. Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive predictive value (PPV) for ccRCC across three independent radiology readers^[12]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC.

For more on TLX250-CDx and Telix’s theranostic kidney cancer program, click here.

TLX250-CDx has not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 
Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

RIYADH, Saudi Arabia, Nov. 19, 2025 /PRNewswire/ — The third edition of the Saudi International Handicrafts Week “Banan” has officially begun. It is held at Princess Nourah bint Abdulrahman University in Riyadh, the capital of the Kingdom of Saudi Arabia, with 400+ artisans from 40+ countries, including Syria, the UAE, Egypt, Oman, Bahrain, and Jordan. The People’s Republic of China is the Guest of Honor for this edition.

The Saudi International Handicrafts Week “Banan” launches its third edition with broad international participation

This year’s edition coincides with the Year of Handicrafts 2025. The Saudi Heritage Commission, one of 11 sector-specific commissions, organizes the event to highlight handicrafts as a vital part of the Kingdom’s cultural identity and strengthen their presence in the creative landscape by providing a platform bringing together prominent artisans worldwide.

As part of the Chinese participation, the Ambassador of the People’s Republic of China to the Kingdom, Zhang Hua, visited the Chinese pavilion, where he observed live demonstrations by traditional art inheritors specially invited to take part in “Banan.” The artisans showcased ancient crafts passed down through generations, engaging visitors widely. The Ambassador praised the event’s organization and the Kingdom’s role in promoting cultural and artistic exchange.

The event also attracted audiences across its diverse zones, particularly the children’s area, “Banan Story,” an interactive space where play becomes educational. Children explore materials, experiment with tools, and create art inspired by world crafts. This area nurtures creativity and introduces young participants to various cultures.

“Banan” is regarded as one of the region’s leading cultural events, offering an international platform to celebrate traditional crafts, empower artisans, and reflect the Kingdom’s growing contribution to cultural and creative industries.

About the Heritage Commission:

Launched in 2020, the Heritage Commission is one of the Ministry of Culture’s 11 sector-specific commissions. It oversees Saudi Arabia’s heritage sector, preserving and promoting the Kingdom’s tangible and intangible heritage. The Commission plans to open several archaeological sites to visitors and supports publishing research on heritage and archaeology.

Learn more: https://heritage.moc.gov.sa/en  | X @MOCHeritage

About the Ministry of Culture:

Saudi Arabia has a rich history of arts and culture. The Ministry develops the cultural economy and enriches the lives of citizens, residents, and visitors. Through its 11 sector-specific commissions, the Ministry preserves heritage while fostering new creative expression.

Find the Ministry on social media: X @MOCSaudi (Arabic); @MOCSaudi_En (English) | Instagram @mocsaudi

The Saudi International Handicrafts Week “Banan” launches its third edition with broad international participation

The Saudi International Handicrafts Week “Banan” launches its third edition with broad international participation

The global lifestyle tech brand celebrates the holiday season with up to 40% off their award-winning hair dryers, toothbrushes, and electric razors.

NEW YORK, Nov. 20, 2025 /PRNewswire/ — Laifen, the global lifestyle technology brand redefining personal care through innovation, design, and performance, is ringing in the holiday season with its most exciting savings to date. From November 19^th to December 5^th, shoppers can enjoy exclusive Black Friday and Cyber Monday offers on LaifenTech.com and Amazon, including the highest discount in brand history—40% off the SE Lite Hair Dryer.

The promotion covers Laifen’s full range of premium personal care innovations, from award-winning hair dryers to next-generation electric razors and advanced electric toothbrushes. In September 2025, Laifen expanded its grooming portfolio with the T1 Pro and P3 Pro Electric Razors, debuting them at IFA with sleek design and advanced technology for a smooth, irritation-free shave. The brand also recently launched the SE 2 High-Speed Hair Dryer, featuring a brushless motor, intelligent temperature control, and ergonomic design for professional-grade styling that protects hair health and shine.

The new launches and the brand’s best-selling products will be discounted this holiday shopping season, so consumers can access these high-tech offerings at an even lower price than usual. The deals include:

• 40% off SE Lite Hair Dryer
• 40% off SE Hair Dryer + Wave SE Bundle
• 40% off Swift Special Hair Dryer + Storage Bag
• 35% off Wave (Aluminum Alloy)
• 35% off Wave (ABS)
• 25% off T1 Pro and P3 Pro Electric Razors
• 20% off Wave SE

In addition to Amazon and LaifenTech.com, Laifen will host the following Black Friday & Cyber Monday sales at their respective retail partners, including:

• Best Buy:
  11/23-12/1: Up to 33% off
• Target:
  11/23-12/1: Up to 40% off
• Nordstrom:
  11/20-12/2: Up to 29% off

Shop the sales now and for more information on Laifen, please visit www.laifentech.com or follow @laifen_tech and @laifentech on social media.

About Laifen: 

Established in 2019, Laifen began with our independently designed and manufactured 110,000 RPM high-speed brushless motor — the innovative core behind our now internationally recognized line of hair dryers. Building on this foundation, we expanded into oral care in 2023 with the launch of the Laifen Wave electric toothbrush, powered by a sensor-controlled servo motor system previously used in robots. In 2025, we redefined the craftsmanship and efficiency of electric shavers with the introduction of the Laifen electric shaver and our in-house high-speed linear motor inspired by the catapult system of aircraft carriers.

media@laifentech.com

NEW YORK, Nov. 20, 2025 /PRNewswire/ — Patient-centered nonprofit organization HS Connect recently hosted the Empower HS: Knowledge and Advocacy Workshop, an educational event designed to help individuals living with Hidradenitis Suppurativa (HS) and their caregivers gain the knowledge and confidence to advocate for themselves. Dimora Medical, a continuous innovator in high-end medical care supplies, supported the event through product donations, joining in the effort to enhance public understanding, improve patient self-management, and advance scientific wound care practices.

The workshop brought together healthcare professionals, researchers, and patient advocates to explore the latest developments in HS research and treatment. The event also underscored the role of education and empathy in combating stigma and improving the quality of life for those affected.

Dimora has long been dedicated to advancing chronic disease care, particularly for conditions like HS that require consistent wound management and emotional resilience. The company’s products are designed to help patients safely and effectively manage wounds at home, minimizing infection risks and supporting healing.

Among its key offerings, the Dimora Skin and Wound Cleanser, an OTC first aid antiseptic, provides broad-spectrum antimicrobial protection through its PHMB-based formula. It effectively eliminates 99.99% of microorganisms within minutes, including MRSA, E. coli, and Pseudomonas aeruginosa, while helping prevent biofilm formation. The cleanser is sting-free, odorless, and pH-balanced at 5.5, creating a gentle environment for long-term use without irritation. With lasting antibacterial efficacy for up to eight weeks after opening, it offers a safe, reliable, and comfortable cleansing experience suitable for both minor injuries and complex wounds.

Complementing this, the Dimora Super Absorbent Dressings are designed to absorb and lock in wound exudate instantly, converting fluid into gel within one second to reduce the risk of maceration. The elastic 360° outward extension ensures a secure yet breathable fit, while the soft silicone contact layer adheres gently to the skin without sticking to the wound bed, allowing painless dressing changes and minimizing secondary injuries. These dressings provide an ideal moist healing environment for a range of exuding wounds, from ulcers and pressure sores to burns and surgical sites.

Through these solutions, Dimora continues to support HS patients in managing daily wound care more comfortably and effectively, helping them maintain dignity and confidence throughout the healing process. By advancing accessible, clinically backed wound care innovations, Dimora seeks to make everyday care simpler, safer, and more humane for patients worldwide.

About Dimora Medical

Dimora, standing for Direct In-Home Medical Options for Recovery and Aid, specializes in advanced wound care products tailored for middle-aged and elderly individuals. With a professional medical background, Dimora Medical is dedicated to enhancing quality of life by simplifying wound management and chronic disease care. The initial wound dressing concept aimed to help caregivers manage wounds efficiently, reducing the risk of secondary injuries. Evolving from wound care expertise to chronic disease management, Dimora Medical offers multi-scenario products to streamline home care, making life comfortable, easy, and convenient.

For more information, please visit: https://dimoramedical.com/.

WASHINGTON, Nov. 20, 2025 /PRNewswire/ — The Standing Committee of CITES, an international body responsible for monitoring trade in animal species, announced the results of its review of animal breeding practices in Cambodia, thanking Cambodia for providing extensive data and relying on science. The report, released on Nov. 12, 2025 in advance of an upcoming Standing Committee meeting, is available at https://cites.org/eng/sc/79/agenda-documents.

Among other positive findings, the report states that Cambodia has customs and inspection procedures in place that are “well-coordinated and integrated through the national single window system, with inspections and documentation supporting transparency.” The report goes on to commend Cambodia, recognizing “Cambodia’s openness and cooperation” throughout the review process and acknowledging “the country’s commitment to improving its legislative framework, enhancing traceability, and aligning with CITES procedures.”

Long-tailed macaques are integral to biomedical research globally due to their close biological similarity to humans. Long-tailed macaques are the most commonly studied nonhuman primate species for drug safety assessment. Research with long-tailed macaques has been crucial for advances in regenerative medicine, immunology, cancer, vaccine development and pharmacology.

Cambodia was historically a major supplier of animal research models to the United States; however, allegations of illegal activity by special interest groups in the U.S. served to reduce imports from Cambodia. The unavailability of research models has put U.S. medical research at risk and has impacted the ability of U.S. researchers to develop new treatments.

“NABR welcomes the latest report from CITES finding that Cambodia is in compliance with international laws and requirements,” NABR President Matthew R. Bailey said. “This report affirms Cambodia’s compliance and demonstrates that animal research models desperately needed in the United States may be obtained from this country.”

“NABR thanks Cambodia for its openness and cooperation throughout this process and stands ready to work with United States and other countries on these matters,” Bailey added.

About the National Association for Biomedical Research
Founded in 1979, NABR is the only 501(c)(6) nonprofit association dedicated to sound public policy for the humane use of animals in biomedical research, education, and testing. Members include more than 340 universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, patient groups, and academic and professional societies who rely on humane and responsible animal research to advance global human and animal health. Learn more about us at https://www.nabr.org/.

Contact: Eva Maciejewski
emaciejewski@nabr.org
(202) 967-8305

KRWQ, launched by IQ in partnership with Frax, hits a key milestone

SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ — KRWQ, the first fiat-backed and multichain stablecoin pegged 1:1 to the South Korean won (KRW), has officially surpassed 1 billion won in total trading volume less than two weeks after launch. The milestone coincides with the activation of AERO emissions on Aerodrome, expanding incentives for the KRWQ-USDC pool on Base and supporting deeper liquidity.

KRWQ, launched by IQ in partnership with Frax, to surpass ₩1 billion in trading volume

Developed by IQ in partnership with Frax, KRWQ combines IQ’s established presence in the Korean market with Frax’s proven stablecoin infrastructure. Frax’s upcoming FraxNet network provides the technical foundation for scalable, asset-backed stablecoins, and KRWQ extends this model to the Korean won.

To enable interoperability, KRWQ uses LayerZero’s OFT (Omnichain Fungible Token) standard and Stargate bridge, allowing the stablecoin to move seamlessly across blockchains with unified liquidity and zero-slippage transfers.

“Crossing one billion won in trading volume so quickly shows the market’s need for a Korean won stablecoin,” said Navin Vethanayagam, Chief Brain of IQ. “With AERO emissions now live on Aerodrome, KRWQ is on track to become the foundational KRW asset on Base and beyond.”

“Frax focuses on secure, scalable stablecoin infrastructure,” said Sam Kazemian, Founder and CEO of Frax. “KRWQ’s early momentum shows how new fiat-backed stablecoins can integrate seamlessly with global DeFi liquidity while reflecting the same principles that power frxUSD and the Frax ecosystem.”

“Surpassing ₩1B in volume so quickly not only underscores the growing global interest in KRW stablecoins among the Asian currencies, but also shows how building on multiple chains can result in immediate results,” said Alex Lim, Head of APAC at LayerZero and Executive Director of the Asia Stablecoin Alliance. “KRWQ demonstrates how regional currencies can operate seamlessly across ecosystems through interoperable, on-chain frameworks.”

Minting and redemption of KRWQ are limited to Eligible KYC’d counterparties, including exchanges, market makers, and integrated institutional partners. At this time, KRWQ is intended for use in global DeFi markets and is not being marketed or offered to Korean residents.

About KRWQ

KRWQ is the first fiat-backed stablecoin pegged 1:1 to the Korean won. Developed by IQ in partnership with Frax, KRWQ brings the Korean won on chain as a secure, compliant, and scalable settlement layer for global markets. KRWQ is built on proven infrastructure with a controlled mint and redeem framework designed for exchanges and market makers.

For more information, visit www.KRWQ.cash.

Media contact: Gary Bird, gary@43pr.com